Edwards Lifesciences (EW)

• Market cap: $41.2B
• 1 day: -0.11%
• 5 days: -1.08%
• 1 month: -5.86%
• 3 months: 1.91%
• 6 months: -20.08%
• Year to date: -3.87%
• 1 year: -5.47%
• 5 years: -12.28%
• 10 years: 225.92%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Employees: 19,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more call options, than puts

Call options by funds: $740M | Put options by funds: $297M

4.0% less ownership

Funds ownership: 84.23% [Q2] → 80.23% (-4.0%) [Q3]

8% less funds holding

Funds holding: 1,281 [Q2] → 1,173 (-108) [Q3]

27% less repeat investments, than reductions

Existing positions increased: 361 | Existing positions reduced: 493

32% less capital invested

Capital invested by funds: $46.9B [Q2] → $31.9B (-$14.9B) [Q3]

38% less first-time investments, than exits

New positions opened: 140 | Existing positions closed: 227

57% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 6 (-8) [Q3]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 14% downside
• Avg. target: $78 11% upside
• High target: $90 29% upside

12 analyst ratings

• positive: 5 42%
• neutral: 6 50%
• negative: 1 8%

Wolfe Research Mike Polark 60% 1-year accuracy 6 / 10 met price target	14% downside $60	Underperform Downgraded	16 Jan 2025
B of A Securities Travis Steed 0% 1-year accuracy 0 / 5 met price target	29% upside $90	Buy Upgraded	16 Dec 2024
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target	19% upside $83	Buy Maintained	11 Dec 2024
Goldman Sachs David Roman 46% 1-year accuracy 6 / 13 met price target	29% upside $90	Buy Maintained	5 Dec 2024
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target	12% upside $78	Hold Reiterated	5 Dec 2024